All In Biotech

Drug Trial Radar · NCT05023018

NEO100 and High-Grade Meningioma

An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 1, 2022

Primary completion

Dec 30, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Neonc Technologies, Inc.Industry
Sponsor type
Industry
First posted
Aug 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.

Conditions

  • Residual, Progressive or Recurrent Grade II or III Meningioma

Interventions

  • NEO100Drug

    NEO100 is a purified form of perillyl alcohol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival as six months (PFS6).Time frame: 6 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California · Recruiting

  • Sutter Health Research Institute

    San Francisco, California · Recruiting

  • Saint John Cancer Institute

    Santa Monica, California · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

  • Baylor Scott and White

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.